Asahi Kasei expands its global pharmaceutical footprint with the acquisition of Aicuris, strengthening its pipeline in infectious diseases and advancing treatments for immunocompromised patients.
Global Healthcare Strategy | 21/04/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy